RGEN Stock Recent News

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2024 Corporate Sustainability Report and related reporting framework disclosures. Themed “Perspectives on Progress”, this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities and Partnerships & Pathways. Also included in the 2024 Corporate Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and two key reporting frameworks: the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB), now part of the IFRS Sustainability Alliance.

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to value investors?

RGEN reports better-than-expected first-quarter results. The company increases its total revenue (on a reported basis) guidance for 2025.

Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Dan Arias - Stifel Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Subbu Nambi - Guggenheim Securities Brendan Smith - TD Cowen Doug Schenkel - Wolf Research Matt Stanton - Jefferies Dan Leonard - UBS Operator Good day, ladies and gentlemen, and welcome to Repligen Corporation's First Quarter of 2025 Earnings Conference Call. My name is Dorwin, and I will be your coordinator.

Repligen (RGEN) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.28 per share a year ago.

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.

Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Repligen (RGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.